To date, similar results are obtained with one additional clinically approved anti-cancer mAb, anti-Her2 (Herceptin), as well as other non-therapeutic mAbs such as anti-CD4 (OKT4) (unpublished data). The gene discussed is CD4; the disease is cancer.